Because liposarcoma is rare, commonly recurs, and has evolving treatments, it cannot be overemphasized that patients should be referred to specialized cancer treatment centers where a larger ...
Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.
Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback